DRUG · Mapped RxNorm record
Candesartan
Normalized identity: candesartanView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker
NCT01444833
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedChanges After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Hypertensionunresolved
Interventions
CandesartanDRUG · verified · RxNorm: candesartan
Sponsors & collaborators
Slovak Academy of Scienceslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01444833 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.